National Institutes of Health

Description

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for support of preclinical evaluation, planning for and conduct of proof-of-concept clinical studies for Mycobacterium tuberculosis (TB) treatment that will be applicable in the context of HIV co-infection using host-directed agents already approved for clinical use or in late-stage clinical trials for other conditions. Host-directed therapies (HDT) for TB that may also have activity against HIV, either directly or by enhancing immunologic reactions, are of particular interest. Funds from the NIH will be made available through the UH2/UH3 cooperative agreement award mechanism. The initial UH2 award (up to two years) will support the development of critical preclinical data, development of study partnerships, and development of the proof-of-concept (POC) trial protocol and all supporting plans and documentation. Once UH2 pre-clinical and clinical milestones have been met, the UH3 award (up to 3 years) may be made to support the planned POC clinical trial.

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV